Cargando…
Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial
Objectives: The objective of this study is to evaluate the effects of a soy drink with a high concentration of isoflavones (ViveSoy®) on climacteric symptoms. Methods: An open-label, controlled, crossover clinical trial was conducted in 147 peri- and postmenopausal women. Eligible women were recruit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898139/ https://www.ncbi.nlm.nih.gov/pubmed/26806546 http://dx.doi.org/10.3109/09513590.2015.1132305 |
_version_ | 1782436299261607936 |
---|---|
author | Tranche, Salvador Brotons, Carlos Pascual de la Pisa, Beatriz Macías, Ramón Hevia, Eduardo Marzo-Castillejo, Mercè |
author_facet | Tranche, Salvador Brotons, Carlos Pascual de la Pisa, Beatriz Macías, Ramón Hevia, Eduardo Marzo-Castillejo, Mercè |
author_sort | Tranche, Salvador |
collection | PubMed |
description | Objectives: The objective of this study is to evaluate the effects of a soy drink with a high concentration of isoflavones (ViveSoy®) on climacteric symptoms. Methods: An open-label, controlled, crossover clinical trial was conducted in 147 peri- and postmenopausal women. Eligible women were recruited from 13 Spanish health centers and randomly assigned to one of the two sequence groups (control or ViveSoy®, 500 mL per day, 15 g of protein and 50 mg of isoflavones). Each intervention phase lasted for 12 weeks with a 6-week washout period. Changes on the Menopause Rating Scale and quality of life questionnaires, as well as lipid profile, cardiovascular risk and carbohydrate and bone metabolism were assessed. Statistical analysis was performed using a mixed-effects model. Results: A sample of 147 female volunteers was recruited of which 90 were evaluable. In both sequence groups, adherence to the intervention was high. Regular consumption of ViveSoy® reduced climacteric symptoms by 20.4% (p = 0.001) and symptoms in the urogenital domain by 21.3% (p < 0.05). It also improved health-related quality life by 18.1%, as per the MRS questionnaire (p <0.05). Conclusion: Regular consumption of ViveSoy® improves both the somatic and urogenital domain symptoms of menopause, as well as health-related quality of life in peri- and postmenopausal women. |
format | Online Article Text |
id | pubmed-4898139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-48981392016-06-20 Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial Tranche, Salvador Brotons, Carlos Pascual de la Pisa, Beatriz Macías, Ramón Hevia, Eduardo Marzo-Castillejo, Mercè Gynecol Endocrinol Soy and Climacteric Symptoms Objectives: The objective of this study is to evaluate the effects of a soy drink with a high concentration of isoflavones (ViveSoy®) on climacteric symptoms. Methods: An open-label, controlled, crossover clinical trial was conducted in 147 peri- and postmenopausal women. Eligible women were recruited from 13 Spanish health centers and randomly assigned to one of the two sequence groups (control or ViveSoy®, 500 mL per day, 15 g of protein and 50 mg of isoflavones). Each intervention phase lasted for 12 weeks with a 6-week washout period. Changes on the Menopause Rating Scale and quality of life questionnaires, as well as lipid profile, cardiovascular risk and carbohydrate and bone metabolism were assessed. Statistical analysis was performed using a mixed-effects model. Results: A sample of 147 female volunteers was recruited of which 90 were evaluable. In both sequence groups, adherence to the intervention was high. Regular consumption of ViveSoy® reduced climacteric symptoms by 20.4% (p = 0.001) and symptoms in the urogenital domain by 21.3% (p < 0.05). It also improved health-related quality life by 18.1%, as per the MRS questionnaire (p <0.05). Conclusion: Regular consumption of ViveSoy® improves both the somatic and urogenital domain symptoms of menopause, as well as health-related quality of life in peri- and postmenopausal women. Taylor & Francis 2016-06-02 2016-01-25 /pmc/articles/PMC4898139/ /pubmed/26806546 http://dx.doi.org/10.3109/09513590.2015.1132305 Text en © 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/Licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/Licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Soy and Climacteric Symptoms Tranche, Salvador Brotons, Carlos Pascual de la Pisa, Beatriz Macías, Ramón Hevia, Eduardo Marzo-Castillejo, Mercè Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial |
title | Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial |
title_full | Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial |
title_fullStr | Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial |
title_full_unstemmed | Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial |
title_short | Impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial |
title_sort | impact of a soy drink on climacteric symptoms: an open-label, crossover, randomized clinical trial |
topic | Soy and Climacteric Symptoms |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4898139/ https://www.ncbi.nlm.nih.gov/pubmed/26806546 http://dx.doi.org/10.3109/09513590.2015.1132305 |
work_keys_str_mv | AT tranchesalvador impactofasoydrinkonclimactericsymptomsanopenlabelcrossoverrandomizedclinicaltrial AT brotonscarlos impactofasoydrinkonclimactericsymptomsanopenlabelcrossoverrandomizedclinicaltrial AT pascualdelapisabeatriz impactofasoydrinkonclimactericsymptomsanopenlabelcrossoverrandomizedclinicaltrial AT maciasramon impactofasoydrinkonclimactericsymptomsanopenlabelcrossoverrandomizedclinicaltrial AT heviaeduardo impactofasoydrinkonclimactericsymptomsanopenlabelcrossoverrandomizedclinicaltrial AT marzocastillejomerce impactofasoydrinkonclimactericsymptomsanopenlabelcrossoverrandomizedclinicaltrial |